IndiaTuberculosis profile
Population  2018 1 353 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 2 690 (1 840–3 700) 199 (136–273)
HIV-positive TB incidence 92 (63–126) 6.8 (4.6–9.3)
MDR/RR-TB incidenceºº 130 (77–198) 9.6 (5.7–15)
HIV-negative TB mortality 440 (410–470) 32 (30–35)
HIV-positive TB mortality 9.7 (5.7–15) 0.72 (0.42–1.1)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 2.8% (2.3–3.5)
Previously treated cases 14% (14–14)
TB case notifications, 2018  
Total new and relapse 1 994 000
          - % tested with rapid diagnostics at time of diagnosis 50%
          - % with known HIV status 72%
          - % pulmonary 82%
          - % bacteriologically confirmedººº 57%
          - % children aged 0-14 years 6%
          - % women 34%
          - % men 60%
Total cases notified 2 155 894
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 74% (54–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 17% (12–24)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 49 047 3%
          - on antiretroviral therapy 44 080 90%
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 46%
          - Previously treated cases 91%
Laboratory-confirmed cases* MDR/RR-TB: 58 347, XDR-TB: 3 400
Patients started on treatment* ** MDR/RR-TB: 46 569, XDR-TB: 2 724
MDR/RR-TB cases tested for resistance to second-line drugs 38 236
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 81% 1 568 392
Previously treated cases, excluding relapse, registered in 2017 56% 146 982
HIV-positive TB cases registered in 2017 71% 31 213
MDR/RR-TB cases started on second-line treatment in 2016 48% 33 197
XDR-TB cases started on second-line treatment in 2016 30% 2 464
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment 17%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
26% (24–28)
TB financing, 2019  
National TB budget (US$ millions) 583
Funding source: 77% domestic, 23% international, 0% unfunded
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-12-10 Data: www.who.int/tb/data